scispace - formally typeset
J

John Macdougall

Researcher at Sunnybrook Health Sciences Centre

Publications -  48
Citations -  1787

John Macdougall is an academic researcher from Sunnybrook Health Sciences Centre. The author has contributed to research in topics: Nucleic acid methods & Cancer. The author has an hindex of 13, co-authored 46 publications receiving 1645 citations.

Papers
More filters
Journal ArticleDOI

Establishment and Characterization of First Trimester Human Trophoblast Cells with Extended Lifespan

TL;DR: Apart from their ability to sustain prolonged growth in culture, the transfected HTR-8/SVneo cells share a number of phenotypic properties with the parental trophoblast cells, which may prove to be an important tool for the study of placental function and/or tumor progression.
Journal ArticleDOI

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.

TL;DR: These studies demonstrate that IPI-145 exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation, and support the hypothesis that inhibition of immune function can be achieved through PI3K-δ and PI3k-γ blockade.
Journal ArticleDOI

Resistance of Malignant Trophoblast Cells to both the Anti-proliferative and Anti-invasive Effects of Transforming Growth Factor-β

TL;DR: The findings suggest that choriocarcinoma cells may become refractory to the mechanisms which control normal trophoblast proliferation and invasiveness, and Concurrent resistance to antiproliferative and anti-invasive molecules such as TGF-beta may be highly relevant to tumor progression.
Journal Article

The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells.

TL;DR: This work examined cell lines derived from early stage primary melanomas in which patients were cured of their disease and compared the results to those obtained with cell lines established from advanced stage primary lesions or metastases, finding that 80% of cell lines examined fromEarly stage lesions constitutively produced only the 72-kDa gelatinase A but never the 92-k da gelatinase B.
Journal ArticleDOI

Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB

TL;DR: The results suggest that CR011-vcMMAE may provide therapeutic benefit in malignant melanoma and that the antibody–drug conjugate produced complete regressions but the equivalent doses of free monomethylauristatin E or unconjugated antibody did not show anti-tumor effects.